Is NF-kB persistently activated in ovarian cancer patients with drug resistance?
- User
Is NF-kB persistently activated in ovarian cancer patients with drug resistance?
Assistant
Yes, NF-κB is persistently activated in ovarian cancer patients with drug resistance, and this activation plays a significant role in the development of chemoresistance.
Evidence of Persistent NF-κB Activation in Drug-Resistant Ovarian Cancer
- Studies have shown that increased NF-κB activity is associated with poor disease progression in ovarian cancer and confers resistance to cisplatin-induced apoptosis, a common chemotherapy drug used in ovarian cancer treatment[1].
- NF-κB signaling activation, particularly through the inhibitor of NF-κB kinase β (IKKβ), increases the aggressiveness of ovarian cancer and is linked to chemoresistant variants of ovarian cancer cells[1].
- Nuclear accumulation of the NF-κB subunit p65 in ovarian cancer tissues correlates with chemotherapy response and survival, but in chemoresistant cancer cells, NF-κB acts as an oncogene promoting tumor growth and resistance[1].
- Elevated expression of NF-κB proteins (p65 and p50) and activating kinases (IKKβ and IKKε) are frequently observed in ovarian cancer and are associated with worse overall survival and chemoresistance[2].
- NF-κB signaling promotes anti-apoptotic functions, cancer stem cell maintenance, metastasis, and immune evasion in ovarian cancer, all of which contribute to chemoresistance and disease recurrence[2].
- Blocking NF-κB activation in ovarian cancer cells enhances apoptosis and increases sensitivity to cisplatin, confirming its role in drug resistance[5].
- Chemotherapy itself can induce NF-κB activation, which in turn promotes survival pathways that reduce the efficacy of drugs like cisplatin and paclitaxel[1][7][8].
- NF-κB activation is linked to the regulation of multiple genes involved in proliferation, apoptosis inhibition, angiogenesis, and metastasis, all contributing to the chemoresistant phenotype in ovarian cancer[5][7].
Mechanistic Insights
- NF-κB can be activated via canonical and non-canonical pathways in ovarian cancer, responding to inflammatory cytokines and tumor microenvironment signals, which sustain its persistent activation[2].
- The pathway interacts with other signaling cascades such as PI3K/AKT and MAPK, further promoting survival and resistance mechanisms[1][7].
- NF-κB regulates the expression of PD-L1, contributing to immune evasion and chemotherapy-induced immune tolerance in ovarian cancer[5].
- Non-coding RNAs and other molecular factors modulate NF-κB activity, influencing drug resistance through apoptosis inhibition and other cellular changes[6].
Summary
NF-κB is persistently activated in ovarian cancer patients who develop resistance to chemotherapy. This persistent activation supports tumor cell survival, inhibits apoptosis, promotes cancer stem cell characteristics, and facilitates immune evasion, all of which contribute to the failure of chemotherapy. Targeting NF-κB signaling is considered a promising strategy to overcome chemoresistance in ovarian cancer, although clinical application requires careful modulation due to NF-κB’s roles in normal physiological processes[1][2][5][7][8].
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.